Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Currently Amended) A compound of formula I



in salt or zwitterionic form wherein

R^1 and R^3 are each independently a C_3-C_{15}-carbocyclic group or a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur;

R^2 is hydrogen, hydroxy, or C_1-C_4-alkyl optionally substituted by hydroxy;

~~L and M are (a bond and -CH_2-CH_2-), (-CH_2- and -CH_2-CH_2-) or (-CH_2-CH_2- and -CH_2-) respectively and~~ J is C_1-C_2-alkylene~~,~~

~~or L and M are (-CH_2- and -CH_2-CH_2-) or (-CH_2-CH_2- and -CH_2-) respectively and J is a bond~~;

R^4 is C_1-C_4-alkyl;

R^5 is C_1-alkyl substituted by ~~-SO-R^6, -S(=O)$_2$-R^6,~~ -CO-R^6, ~~-CO-O-R^6,~~ or -CO-NH-R^6 ~~or -R^7~~,

or R^5 is C_2-C_{10}-alkyl substituted by -O-R^6, ~~-S-R^6, -SO-R^6, -S(=O)$_2$-R^6, -CO-R^6,~~ -O-CO-R^6, ~~-CO-O-R^6, -NH-CO-R^6, -CO-NH-R^6, -R^7~~ or -R^8,

or R^5 is C_2-C_{10}-alkenyl or C_2-C_{10}-alkynyl optionally substituted by ~~-R^7 or~~ -R^8;

R^6 is a C_3-C_{15}-carbocyclic group or a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur,

or R^6 is C_1-C_{10}-alkyl optionally substituted by C_1-C_{10}-alkoxy, ~~-O-R^7~~, -O-R^8 a C_3-C_{15}-carbocyclic group or a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur; and

~~R^7 is a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur; and~~

R^8 is a C_3-C_{15}-carbocyclic group.

Claim 2. (Currently Amended) A compound according to claim 1, wherein

R^1 and R^3 are each independently a C_3-C_{15}-carbocyclic group or a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur;

R^2 is hydroxy;

~~L and M are (a bond and -CH_2-CH_2-), (-CH_2- and -CH_2-CH_2-) or (-CH_2-CH_2- and -CH_2-) respectively and~~ J is C_1-C_2-alkylene~~,~~

~~or L and M are ($-CH_2-$ and $-CH_2-CH_2-$) or ($-CH_2-CH_2-$ and $-CH_2-$) respectively and J is a bond~~;
R^4 is C_1-C_4-alkyl;
R^5 is C_1-alkyl substituted by $-CO-R^6$ or $-CO-NH-R^6$,
or R^5 is C_2-C_{10}-alkyl substituted by $-O-R^6$, ~~$-S-R^6$~~, $-O-CO-R^6$ or $-R^8$,
or R^5 is C_2-C_{10}-alkenyl or C_2-C_{10}-alkynyl optionally substituted by $-R^8$;
R^6 is a C_3-C_{15}-carbocyclic group,
or R^6 is C_1-C_{10}-alkyl optionally substituted by C_1-C_{10}-alkoxy, $O-R^8$ or a C_3-C_{15}-carbocyclic group; and
R^8 is a C_3-C_{15}-carbocyclic group.

Claim 3. (Currently Amended) A compound according to claim 2, wherein
R^1 and R^3 are each independently a C_3-C_{10}-carbocyclic group, preferably phenyl, or a 5- to 9-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur, preferably thienyl;
R^2 is hydroxy;
~~L and M are (a bond and $-CH_2-CH_2-$), ($-CH_2-$ and $-CH_2-CH_2-$) or ($-CH_2-CH_2-$ and $-CH_2-$) respectively and~~ J is C_1-C_2-alkylene~~,~~
~~or L and M are ($-CH_2-$ and $-CH_2-CH_2-$) or ($-CH_2-CH_2-$ and $-CH_2-$) respectively and J is a bond~~;
R^4 is C_1-C_4-alkyl;
R^5 is C_1-alkyl substituted by $-CO-R^6$ or $-CO-NH-R^6$,
or R^5 is C_2-C_5-alkyl substituted by $-O-R^6$, ~~$-S-R^6$~~, $-O-CO-R^6$ or $-R^8$,
or R^5 is C_2-C_4-alkenyl or C_2-C_8-alkynyl optionally substituted by $-R^8$;
R^6 is a C_3-C_{10}-carbocyclic group, preferably phenyl,
or R^6 is C_1-C_{15}-alkyl optionally substituted by C_1-C_4-alkoxy, $O-R^8$ or a C_3-C_{10}-carbocyclic group; and
R^8 is a C_3-C_{10}-carbocyclic group, preferably phenyl.

Claims 4-7. (Canceled)

Claim 8. (Currently Amended): A compound according to claim 1, which is also a compound of formula XVI



XVI

where T is as shown in the following table:

T



















Claim 9. (Currently Amended): A compound according to claim 1, which is also a compound of formula XVII



XVII

where T is as shown in the following table:

T


















Claim 10. (Cancelled)

Claim 11. (Previously Presented): A pharmaceutical composition comprising as active ingredient a compound according to claim 1.

Claims 12-15. (Cancelled)

Claim 16. (Currently Amended): A process for the preparation of a compound of formula I as claimed in claim 1 which comprises:

(i) (A) reacting a compound of formula II



II

or a protected form thereof where R^1, R^2, R^3, R^4, and J, — are as defined in claim 1, with a compound of formula III

III

where R^5 is as defined in claim 1 and X is chloro, bromo or iodo;

(B) reacting a compound of formula IV



IV

or a protected form thereof where R^1, R^2, R^3, R^5, J, L and M are as defined in claim 1, with a compound of formula V

V

where R^4 is as defined in claim 1 and X is chloro, bromo or iodo;

~~(C) for the preparation of compounds of formula I where R^5 is -Q-NH-CO-R^6, reacting a compound of formula VI~~



VI

~~or a protected form thereof where R^1, R^2, R^3, R^4, J, L and M are as defined in claim 1 and Q is C_1-C_{10}-alkylene, with a compound of formula VII~~



~~VII~~

~~or an amide-forming derivative thereof wherein R^6 is as defined in claim 1; or~~

~~(D) for the preparation of compounds of formula I where R^5 is C_1-C_{10}-alkyl substituted by a C_3-C_{15}-carbocyclic group that is substituted by carboxy, converting a compound of formula I where R^1, R^2, R^3, R^4, J, L and M are as defined in claim 1 and R^5 is C_1-C_{10}-alkyl substituted by a C_3-C_{15}-carbocyclic group that is substituted by either -COO-C_6-C_{10}-aryl or -COO-C_7-C_{15}-aralkyl; and~~

(ii) recovering the product in salt or zwitterionic form.

Claim 17. (Currently Amended): A compound of formula VI



VI

in salt or zwitterionic form wherein

R^1 and R^3 are each independently a C_3-C_{15}-carbocyclic group or a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur;

R^2 is hydrogen, hydroxy, or C_1-C_4-alkyl optionally substituted by hydroxy;

~~L and M are (a bond and -CH_2-CH_2-), (-CH_2- and -CH_2-CH_2-) or (-CH_2-CH_2- and -CH_2-) respectively and~~ J is C_1-C_2-alkylene~~,~~

~~or L and M are (-CH_2- and -CH_2-CH_2-) or (-CH_2-CH_2- and -CH_2-) respectively and J is a bond~~;

R^4 is C_1-C_4-alkyl; and

Q is C_1-C_{10}-alkylene.

Claim 18. (Original): A pharmaceutical composition according to claim 11 wherein the compound is a single enantiomer.

Claim 19. (Cancelled)

Claim 20. (Withdrawn - Original): A method of treating a condition mediated by the muscarinic M3 receptor in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound of formula I as defined in claim 1 in free form or in the form of a pharmaceutically acceptable salt.

Claim 21. (Withdrawn - Original): A method of treating an inflammatory or obstructive airways disease in a subject in need of such treatment, which comprises administering to said subject

an effective amount of a compound of formula I as defined in claim 1 in free form or in the form of a pharmaceutically acceptable salt.

Claim 22. (Withdrawn - Original): A method according to claim 20, in which the compound of formula I is a single enantiomer.